MX378486B - Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo. - Google Patents

Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo.

Info

Publication number
MX378486B
MX378486B MX2017001096A MX2017001096A MX378486B MX 378486 B MX378486 B MX 378486B MX 2017001096 A MX2017001096 A MX 2017001096A MX 2017001096 A MX2017001096 A MX 2017001096A MX 378486 B MX378486 B MX 378486B
Authority
MX
Mexico
Prior art keywords
disorders
sub
halogen
lower alkoxy
lower alkyl
Prior art date
Application number
MX2017001096A
Other languages
English (en)
Other versions
MX2017001096A (es
Inventor
Giuseppe Cecere
Guido Galley
Hong Shen
Philippe Pflieger
Roger Norcross
Yimin Hu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2017001096A publication Critical patent/MX2017001096A/es
Publication of MX378486B publication Critical patent/MX378486B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula (ver Fórmula) en la que L es un enlace, -C(O)NH-, -NHC(O)-, -CH2NHC(O)-, CH2C(O)NH-, -CH2NH-, -NH- o -NHC (O) NH-; R1 es hidrógeno, alquilo inferior, halógeno, alcoxi inferior-alquilo, alcoxi inferior sustituido con halógeno, alquilo inferior sustituido con halógeno o es fenilo o heteroarilo seleccionado entre el grupo que consiste en piridinilo, pirimidinilo, pirazinilo o pirazolilo, y en el que el fenilo y el heteroarilo están opcionalmente sustituidos con uno, dos o tres sustituyentes seleccionados entre el grupo que consiste en halógeno, alquilo inferior, alcoxi inferior, alquilo inferior sustituido con halógeno, alcoxi inferior sustituido con halógeno, cicloalquilo o O-CH2- cicloalquilo; o a una sal de adición de ácidos farmacéuticamente aceptable de los mismos, a todas las mezclas racémicas, a todos sus enantiómeros correspondientes y/o isómeros ópticos, que puede usarse para el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, trastorno de déficit de atención e hiperactividad (TDAH), trastornos relacionados con el estrés, trastornos psicóticos, esquizofrenia, enfermedades neurológicas, enfermedad de Parkinson, trastornos neurodegenerativos, enfermedad de Alzheimer, epilepsia, migraña, hipertensión, abuso de sustancias, trastornos metabólicos, trastornos alimentarios, diabetes, complicaciones diabéticas, obesidad, dislipidemia, trastornos de consumo y asimilación de energía, trastornos de mal funcionamiento de la homeostasis de la temperatura corporal, trastornos del sueño y del ritmo circadiano, y trastornos cardiovasculares.
MX2017001096A 2014-08-01 2015-07-29 Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo. MX378486B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2014/083549 WO2016015333A1 (en) 2014-08-01 2014-08-01 2-oxa-5-azabicyclo [2.2.1] heptan-3-yl derivatives
PCT/EP2015/067353 WO2016016292A1 (en) 2014-08-01 2015-07-29 2-oxa-5-azabicyclo[2.2.1]heptan-3-yl derivatives

Publications (2)

Publication Number Publication Date
MX2017001096A MX2017001096A (es) 2017-04-27
MX378486B true MX378486B (es) 2025-03-11

Family

ID=53758230

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017001096A MX378486B (es) 2014-08-01 2015-07-29 Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo.

Country Status (11)

Country Link
US (1) US9790230B2 (es)
EP (1) EP3174886B1 (es)
JP (1) JP6364121B2 (es)
KR (1) KR101911651B1 (es)
CN (1) CN106661043B (es)
AR (1) AR101359A1 (es)
CA (1) CA2954209C (es)
MX (1) MX378486B (es)
RU (1) RU2697651C2 (es)
TW (1) TWI583687B (es)
WO (2) WO2016015333A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS60825B1 (sr) * 2016-03-17 2020-10-30 Hoffmann La Roche Aktivnost derivata 5-etiol-4-metil-pirazol-3-karboksamida kao agonista taar-a
EP3463359A4 (en) * 2016-06-02 2020-08-26 Purdue Pharma LP TRACE AMINE RECEPTOR 1 AGONISTS AND PARTIAL PAIN AGONISTS
CN106187911A (zh) * 2016-07-04 2016-12-07 烟台凯博医药科技有限公司 2‑三氟甲基嘧啶‑4‑羧酸及其衍生物和制备方法
JP7455581B2 (ja) 2017-05-12 2024-03-26 リサーチ トライアングル インスティテュート Cb1アロステリック・モジュレーターとしてのジアリール尿素
US20230416199A1 (en) * 2020-10-23 2023-12-28 Icahn School Of Medicine At Mount Sinai Inhibitors of amino acid transport
CN114874143A (zh) * 2021-02-05 2022-08-09 上海翰森生物医药科技有限公司 含吡唑类衍生物调节剂、其制备方法和应用
WO2023033681A1 (en) 2021-09-01 2023-03-09 Limited Liability Company «Excellena Research And Development» (Llc «Excellena») Substituted 2-(5-aryl-4 h-1,2,4-triazol-3-yl)ethanamines as modulators of trace amine-associated receptor 1 (taar1)
WO2023033679A1 (en) * 2021-09-01 2023-03-09 Limited Liability Company «Excellena Research And Development» (Llc «Excellena») (azacycloalkyl)methoxy-substituted benzamides as modulators of trace amine-associated receptor 1 (taar1)
WO2023033680A1 (en) 2021-09-01 2023-03-09 Limited Liability Company «Excellena Research And Development» (Llc «Excellena») Substituted 2,3,4,5-tetrahydrobenzo[ f][1,4]oxazepines as modulators of trace amine-associated receptor 1 (taar1)
KR20240096681A (ko) * 2021-11-04 2024-06-26 상하이 한서 바이오메디컬 컴퍼니 리미티드 2-(아릴-2-일)모르폴린 및 이의 중수소화 유도체, 제조 방법과 응용
WO2023156565A1 (en) * 2022-02-16 2023-08-24 Awakn Ls Europe Holdings Limited Bridged ring compounds and their therapeutic use as cns agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1012172B (zh) * 1984-08-24 1991-03-27 北京医学科学院药物研究所 新型黄皮酰胺类化合物的分离和提取方法
DE3431257A1 (de) * 1984-08-24 1986-03-06 Bayer Ag, 5090 Leverkusen Neue (delta)-butyrolactame, pharmakologisch aktive zusammensetzungen derselben, verfahren zu ihrer herstellung und ihre medizinische verwendung
DE3927369A1 (de) * 1989-08-19 1991-02-21 Bayer Ag Substituierte n-(chinolin-2-yl-methoxy)benzyl-sulfonyl-harnstoffe
FR2912404B1 (fr) * 2007-02-09 2009-04-10 Sanofi Aventis Sa Derives d'azabicycloalkane,leur preparation et leur application en therapeutique.
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
KR20150065190A (ko) * 2012-11-07 2015-06-12 에프. 호프만-라 로슈 아게 피라진 유도체
LT3149002T (lt) * 2014-05-28 2018-07-10 F. Hoffmann-La Roche Ag 5-oksa-2-azabiciklo[2.2.2]oktan-4-ilo ir 5-oksa-2-azabiciklo[2.2.1]heptan-4-ilo dariniai kaip taar1 moduliatoriai

Also Published As

Publication number Publication date
RU2017104264A3 (es) 2019-02-27
TWI583687B (zh) 2017-05-21
EP3174886A1 (en) 2017-06-07
CA2954209C (en) 2022-08-30
CN106661043B (zh) 2020-01-17
EP3174886B1 (en) 2021-02-17
AR101359A1 (es) 2016-12-14
RU2017104264A (ru) 2018-09-04
WO2016015333A1 (en) 2016-02-04
TW201617349A (zh) 2016-05-16
WO2016016292A1 (en) 2016-02-04
JP6364121B2 (ja) 2018-07-25
BR112016028714A2 (pt) 2017-08-22
KR20170021352A (ko) 2017-02-27
KR101911651B1 (ko) 2018-10-24
CA2954209A1 (en) 2016-02-04
RU2697651C2 (ru) 2019-08-16
MX2017001096A (es) 2017-04-27
CN106661043A (zh) 2017-05-10
US9790230B2 (en) 2017-10-17
US20170137435A1 (en) 2017-05-18
JP2017522353A (ja) 2017-08-10

Similar Documents

Publication Publication Date Title
MX2017001096A (es) Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo.
PH12013501905A1 (en) Heterocyclic amine derivatives
AR088741A1 (es) Derivados de pirazol
MX2016016488A (es) Derivados de azetidina sustituidos como ligandos de receptores asociados a aminas en trazas (taar).
MY176030A (en) Substituted benzamide derivatives
MX354815B (es) Derivados heterociclicos como receptores asociados con las aminas traza (taars).
TW200738645A (en) Use of 4-imidazole derivatives for CNS disorders
ECSP13013073A (es) Derivados de benzamida sustituida
UA113776C2 (xx) Похідні піразолкарбоксаміду як модулятори рецепторів слідових амінів (taar) для застосування при лікуванні різних розладів, таких як депресія, діабет та хвороба паркінсона
MX361761B (es) Derivados de triazol carboxamida.
MX2016008536A (es) Derivados de fluoro-naftilo.
MX377195B (es) Derivados de morfolina-piridina.
MX2016016606A (es) Derivados de 6-amino-5,6,7,8-tetrahidronaftalen-2-ilo o de 3-aminocroman-7-ilo como moduladores de receptores asociados a aminastraza (taar).
MX2016012624A (es) Derivados de 5-oxa-2-azabiciclo[2.2.2]octan-4-ilo y 5-oxa-2-azabiciclo[2.2.1]heptan-4-ilo como modularores de los receptores asociados a la amina de trazas 1 (taar1).
MX2015005721A (es) Derivados de pirazina.
MX349738B (es) Derivados de dihidrooxazol-2-amina.
AR076979A1 (es) 2- aminooxazolinas como ligandos de taar1
MX2016016190A (es) Derivados de pirazino[2,1-a]isoquinolina sustituida para el tratamiento de trastornos del sistema nervioso central.